MannKind Corp.'s (Nasdaq: MNKD) license and collaboration agreement with Sanofi to develop and commercialize Affrezza Inhalation Powder has been terminated. The stock price plummeted 72 cents to $0.73.
MannKind ends agreement with Sanofi
January 05, 2016 at 12:49 PM EST
